Non-invasive Prenatal Testing(NIPT) Market, by Test Type (Panel 1 Test, Panel 2 Test, and Panel 3 Test), by Application (Trisomy, Microdeletion Syndrome, Sex chromosomes abnormalities, and Others), by End User (Hospitals, Diagnostic Laboratories, and Mate

Non-invasive Prenatal Testing(NIPT) Market, by Test Type (Panel 1 Test, Panel 2 Test, and Panel 3 Test), by Application (Trisomy, Microdeletion Syndrome, Sex chromosomes abnormalities, and Others), by End User (Hospitals, Diagnostic Laboratories, and Maternity Centers), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)- Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Noninvasive prenatal testing (NIPT) is also known as noninvasive prenatal screening (NIPS). It is a procedure used to determine the chromosomal abnormalities or disorders of the fetus which generally occur due to missing or an extra copy (aneuploidy) of a chromosome. NIPT examines small deoxyribonucleic acid (DNA) fragments which are circulating in the blood of pregnant woman. These small fragments are freely floating and hence are called cell-free DNA. NIPT is carried out for the detection of trisomy 18, trisomy 13, Down syndrome, and missing or extra copies of X and Y chromosomes. NIPT is found to be useful during the COVID-19 pandemic situation to avoid the risk of infection. The potential to isolate fetal DNA and fetal cells from maternal blood during pregnancy has revealed exciting opportunities for upgraded noninvasive prenatal testing (NIPT).

Market Dynamics

Obtaining reimbursement for tests from payers is expected to offer lucrative growth opportunities for players in the global non-invasive prenatal testing market. Vendors may focus on obtaining insurance coverage for NIPT tests offered by them, considering the high costs of these tests. Moreover, attention towards health education, subsidies for NIPT, and genetic counseling is also expected to aid in growth of the market. For instance, in September 2020, researchers from Fudan University, China, and University College London, U.K., reported that, in China, compared with Zhengzhou participants, a higher proportion of Shenzhen women had heard of NIPT (87.30% vs. 64.03%), were willing to receive NIPT (91.80% vs. 80.43%) and had taken NIPT (83.12% vs. 54.54%), while their satisfaction level was lower.

Key features of the study:

• This report provides an in-depth analysis of the global non-invasive prenatal testing market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2022–2030), considering 2021 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global non-invasive prenatal testing market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include include F. Hoffmann-La Roche Ltd, BGI Group, Berry Genomics Co., Ltd., Illumina, Inc., Eurofin Scientific, Natera, Inc., Sequenom, Inc., Axia Women’s Health , Eluthia, BillionToOne, Inc., Quest Diagnostics Incorporation., Igenomix, Agilent Technologies, Inc., Laboratory Corporation of America Holdings., PerkinElmer, Inc., Thermo Fisher Scientific, Yourgene Health PLC
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global non-invasive prenatal testing market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global non-invasive prenatal testing market

Detailed Segmentation:

• Global Non-Invasive Prenatal Testing Market, By Test Type:
• Panel 1 Test
• Panel 2 Test
• Panel 3 Test
• Global Non-Invasive Prenatal Testing Market, By Application:
• Trisomy
• Microdeletion Syndrome
• Sex Chromosome abnormalities
• Other
• Global Non-Invasive Prenatal Testing Market, By End User:
• Hospitals
• Diagnostic Laboratories
• Maternity Centers
• Global Non-Invasive Prenatal Testing Market, By Region:
• North America
• By Country
• U.S.
• Canada
• Latin America
• By Country
• Brazil
• Mexico
• Argentina
• Rest of Latin America
• Europe
• By Country
• U.K.
• Germany
• France
• Spain
• Italy
• Russia
• Rest of Europe
• Asia Pacific
• By Country
• China
• Japan
• India
• Australia
• South Korea
• ASEAN
• Rest of Asia Pacific
• Middle East
• By Country
• GCC Countries
• Israel
• Rest of Middle East
• Africa
• By Country
• North Africa
• Central Africa
• South Africa
• Company Profiles
• F.Hoffmann-La Roche Ltd
• Company Overview
• Product Portfolio
• Market Presence
• Financial Overview
• Key Developments
• Strategies
• BGI Group
• Berry Genomics Co., Ltd.
• Illumina, Inc.
• Eurofin Scientific
• Natera, Inc.
• Sequenom, Inc.
• Axia Women’s Health
• Eluthia,
• BillionToOne, Inc.
• Quest Diagnostics Incorporation.
• Igenomix
• Agilent Technologies, Inc.
• Laboratory Corporation of America Holdings.
• PerkinElmer, Inc.
• Thermo Fisher Scientific
• Yourgene Health PLC

“*” marked represents similar segmentation in other categories in the respective section.